50岁及以下患者机械瓣与生物瓣主动脉瓣置换的比较
研究1994至2016年643例50岁及以下主动脉瓣置换患者(机械瓣411例、生物瓣232例),倾向评分匹配170对。生物瓣组再次主动脉瓣置换风险更高(13% vs 1.6%,p<0.001),机械瓣组大出血风险更高(8.5% vs 2.2%,p=0.006),但调整后中期和长期生存无差异。作者认为生物瓣可能是一些50岁及以下患者可接受的瓣膜选择,但结果应谨慎看待。
要点
- 生物瓣组再次主动脉瓣置换风险高于机械瓣组(13% vs 1.6%,p<0.001)。
- 机械瓣组大出血风险高于生物瓣组(8.5% vs 2.2%,p=0.006)。
- 调整后两组中期和长期生存无差异。
核心结论
- 生物瓣再次手术风险增加和机械瓣大出血事件增加未反映在两组中期和长期生存差异中。
- 作者认为生物瓣可能是一些50岁及以下患者可接受的瓣膜选择,但结果应谨慎看待。
研究设计与样本
- 回顾性研究,1994年至2016年643例50岁及以下患者接受主动脉瓣置换(机械瓣411例、生物瓣232例),包括合并冠状动脉旁路移植术和二尖瓣手术。
- 采用倾向评分匹配方法得到170对匹配患者,中位观察时间8.1年(范围0至23.6年)。
主要发现
- 总体平均年龄41.9岁,女性占29.3%,生物瓣使用呈增加趋势。
- 匹配患者中两组平均年龄均为43.3岁(p=0.68)。
- 两组手术死亡、卒中、心房颤动、因出血再手术和30天内再入院率均相似。
- 生物瓣组再次主动脉瓣置换风险更高(13% vs 1.6%,p<0.001)。
- 机械瓣组大出血事件风险更高(8.5% vs 2.2%,p=0.006)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated outcomes in younger patients, specifically aged 50 years and younger, after mechanical aortic valve replacement (mAVR) and bioprosthetic AVR (bAVR). METHODS: From 1994 to 2016, 643 patients underwent AVR (411 mAVR and 232 bAVR) at age 50 or younger. Concomitant coronary artery bypass grafting and mitral valve procedures were also included. Propensity score-matching methods resulted in 170 evenly matched patient pairs. Primary end points were operative mortality and long-term survival. Secondary end points were stroke, major bleeding, and redo AVR. Median observation time was 8.1 years (range, 0 to 23.6 years). RESULTS: Overall, mean age was 41.9 years, and 29.3% were women, with an increasing trend toward use of bAVR. Mean age in the matched patients was 43.3 years for both cohorts (p = 0.68). Operative mortality, stroke, atrial fibrillation, reoperation for bleeding, and readmission rates within 30 days were all similar between the two groups. bAVR patients were at higher risk for redo AVR (13% vs 1.6%, p < 0.001), and mAVR patients were at higher risk for major bleeding events (8.5% vs 2.2%, p = 0.006). However, when adjusted, there were no differences in midterm and long-term survival between unmatched and matched cohorts. CONCLUSIONS: The increased risk of reoperation for bAVR and major bleeding incidents for mAVR was not reflected in midterm and long-term survival differences between the two groups. Our results suggest that bAVR may be an acceptable prosthesis choice for some patients aged 50 years and younger, although the results should be taken with caution.
引用
- Hirji SA, Kolkailah AA, Ramirez-Del Val F, et al. Mechanical Versus Bioprosthetic Aortic Valve Replacement in Patients Aged 50 Years and Younger. Ann Thorac Surg. 2018. PMID: 29966596. doi:10.1016/j.athoracsur.2018.05.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。